Fumito Ito

Inflammaging in melanoma: Precision control for optimizing immune checkpoint inhibition

Hisashi Kanemaru, Steven Luong, Yukari Mizukami, Satoshi Fukushima et autres

jp, us (code pays fourni par la source)

73580 Identifying patient and treatment determinants of survival in acral lentiginous melanoma: A TriNetX analysis

Eva Danesh, Avigdor Nosrati, Kayla Danesh, K Butcher et autres

Baseline corticosteroid use and outcomes in non–small cell lung cancer patients receiving immune checkpoint inhibitors, stratified by indication.

Angelina Lim, Kenneth Nguyen, Fumito Ito, Jorge J. Nieva et autres

11184 Background: Baseline systemic corticosteroids are often prescribed to patients with non-small cell lung cancer (NSCLC) initiating immune checkpoint inhibitors (ICIs). Prior studies associating steroids with reduced ICI efficacy have largely treated steroid exposure as binary without accounting for indication. We evaluated …

us (code pays fourni par la source)

Impact of race/ethnicity and the presence of immune-related adverse events on outcomes for non-small cell lung cancer patients treated with immune checkpoint inhibitors

Robert Hsu, Karen Resnick, Peter D. Zang, Travis Larsen et autres

Background: Immune checkpoint inhibitors (ICIs) have changed the treatment landscape for non-small cell lung cancer, but the role of race/ethnicity is not well understood. Design: This is a retrospective study of non-small cell lung cancer (NSCLC) patients receiving ICI. Objective: We evaluated …

us (code pays fourni par la source)

Abstract B058: Longitudinal single cell and TCRβ profiling of a melanoma patient during adjuvant immune checkpoint inhibitor therapy exhibits significant change in immune cell profiles

Joshua Ni, Ryutaro Kajihara, Mark Long, Angelina Lim et autres

Abstract The advent of immune checkpoint inhibitors (ICIs) has revolutionized the treatment landscape for metastatic melanoma. The effectiveness of ICIs administered following curative surgical resection as adjuvant therapy has also been observed in many patients with advanced melanoma. However, the mechanisms by …

us (code pays fourni par la source)

Abstract A052: Safety, immunogenicity and resistance of in situ Immunomodulation with CDX-301, radiotherapy, CDX-1140, and Poly-ICLC in patients with unresectable and metastatic solid tumors: a phase 1 trial

Steven V. Luong, Hisashi Kanemaru, Andrew Lim, Shelly X. Bian et autres

Abstract T-cell exclusion from the tumor microenvironment (TME) correlates with poor prognosis and is a significant obstacle in cancer treatment. Compelling evidence highlights critical roles of conventional type 1 dendritic cells (cDC1s) in eliciting potent antitumor T-cell responses. Our novel combinatorial in …

us (code pays fourni par la source)

Abstract C022: T-cell IL-6 expression defines a subset of memory T cells, and correlates with response to immune checkpoint inhibitors in patients with melanoma

Hisashi Kanemaru, Ryutaro Kajihara, Paul K. Wallace, Brahm H. Segal et autres

Abstract While immune checkpoint inhibitors (ICIs) have revolutionized the treatment for various types of cancer, they benefit only a subset of patients, are costly, and may cause serious immune-related adverse events. Therefore, biomarkers that can predict their efficacy are urgently needed. Growing …

us, jp (code pays fourni par la source)

Dual-edged therapy: corticosteroids in the era of immunotherapy

Angelina Lim, Robert Hsu, J. Nieva, Fumito Ito

Immune checkpoint inhibitors (ICIs) are a cornerstone in the treatment of non-small cell lung cancer (NSCLC), with their primary mechanism arising from their ability to enhance immune function by r...

us (code pays fourni par la source)

Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer.

俊浩 横井, Toshihiro YOKOI, Takaaki OBA, Ryutaro Kajihara et autres